Pharmaceuticals
Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough
SUZHOU, China and ROCKVILLE, Md., June 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical results of olv...
2023-06-05 11:51
2630
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020
* HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. * HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform. * HBM1020 has great potential to address huge unmet medical needs in patients with advanced malig...
2023-06-05 09:01
2655
VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma
SHANGHAI, June 4, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary objective was ...
2023-06-05 08:00
2584
Sanyou launches new European offices and continues to promote global business landscape
SHANGHAI, June 3, 2023 /PRNewswire/ -- In May 2023, following the CIC Boston branch in US, Sanyou opens new offices in The Shard London and CIC Rotterdam respectively, to rapidly promote the globalization of business landscape. Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co., Ltd. ...
2023-06-03 20:05
3856
TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ -- TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs f...
2023-06-02 15:51
2308
NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two cardiovascular indications
HONG KONG, June 1, 2023 /PRNewswire/ -- Akeso Inc. (9926. HK, "Akeso") announced today thatChina's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hyper...
2023-06-02 11:43
2638
GenEros to Present Promising Results of GEC255 Phase I Clinical Trial for Advanced NSCLC Patients with KRAS G12C Mutation
HANGZHOU, China, June 1, 2023 /PRNewswire/ -- GenEros Biopharma Ltd. ("GenEros" or "the Company"), a biopharmaceutical company dedicated to discovering, developing, and commercializing novel medicines for diseases with unmet medical needs, will unveil the preliminary data from the phase I clinica...
2023-06-01 22:15
2761
Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors
SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, and Eikon Therapeutics ("Eikon"), a biotechnology company that is adv...
2023-06-01 20:30
3004
BIORCHESTRA Invited to Present Update on Central Nervous System Lead Program (BMD-001) and IV-Formulated siRNA Data at BIO2023 International Conference
* Presentation:"Successfully Achieving Intravenous (IV)-formulated RNA Delivery to the Brain, Evidence of Efficacy" scheduled for June 08, 2023, 12:00 p.m. ET, Room 104A * Pioneering IV-formulated inert drug delivery platform targeting neurodegenerative diseases * Lead program (BMD-001) adv...
2023-06-01 20:00
2712
Seegene Obtains IVDR Certification for 30 Diagnostic Assays
* Seegene certifies diagnostic assays for digestive, respiratory, women's diseases, and human papillomavirus to meet IVDR requirements * New regulation sets improved standards to ensure higher level of quality, safety, and reliability SEOUL, South Korea, June 1, 2023 /PRNewswire/ -- Seegene I...
2023-06-01 19:00
2676
Xinhua Silk Road: Activity to promote TCM cultural exchanges and cooperation between China and Luxembourg completes success
BEIJING, June 1, 2023 /PRNewswire/ -- An activity to promote traditional
Chinese medicine (TCM) cultural exchanges and cooperation betweenChina and
Luxembourg held recently at the Luxembourg Embassy in China achieved a complete
success.
2023-06-01 17:37
2289
Xinhua Silk Road: Chinese Lingzhi brand Longevity Valley promotes inheritance of a century-old national treasure to Brunei foreign envoys
BEIJING, May 31, 2023 /PRNewswire/ -- A delegation of the renowned Chinese Lingzhi brand, Zhejiang Longevity Valley Botanical Co., Ltd, recently visited the Embassy ofBrunei Darussalam in China to showcase Chinese traditional culture and wisdom of health philosophy embedded in the brand toBrunei....
2023-06-01 09:47
2662
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, May 31, 2023 /PRNewswire/ -- Actin...
2023-05-31 20:58
2925
QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION
BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited ( QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce thatRichard Godfrey will present to potential partners and investors at t...
2023-05-31 19:00
3319
Asieris' progress in MIBC receives renewed attention with its inclusion in ASCO 2023
SHANGHAI, May 31, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176)， a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the phase I clinical data of ANTICIPATE ...
2023-05-31 16:00
2286
Ascentage Pharma's Novel Drug Olverembatinib Recommended for a Breakthrough Therapy Designation in China for the Treatment of SDH-Deficient GIST, the Second BTD for the Drug
SUZHOU, China and ROCKVILLE, Md., May 30, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announcedtoday that the Center for Drug Evaluation (CDE) of China Na...
2023-05-31 10:20
2388
iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome
* It was confirmed the presence of Prophage and Jamphage in the Alkalihalobacillus clausii * Prophage and Jamphage are expected to play a substantial role in bacterial survival and immune regulation in the body. BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ...
2023-05-30 10:15
2363
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer * FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US,Canada and most European countries * T...
2023-05-29 16:51
3807
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023
* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart in combination of toripalimab showed acceptable safety profile in HCC * Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZH...
2023-05-29 09:42
2747
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will be rele...
2023-05-28 21:00
3944
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8500